Navigation Links
Particle in Medical Technology

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

Results support that Novavax's Recombinant Technology May Offer a Powerful, New Approach for Development of the Next Generation of Influenza Vaccines with Broad Protection Against Multiple Strains ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) announced today favo...

IBA and Elekta Initiate Global Particle Therapy Program at ASTRO

LOS ANGELES, Oct. 27 /PRNewswire/ -- IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) and Elekta AB (publ) (Stockholm, Sweden: EKTA.ST), today announced a global particle therapy collaboration program to optimize the seamless integration of proton therapy delivery and in...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its T...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

...ax, Inc. (Nasdaq: NVAX ) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under cur...s diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinan...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

...eroids or IsoCrom. PARI's Comparative in-vitro assessment of IsoCrom & a novel 6% DSCG formulation Sophisticated aerodynamic droplet and particle size assessments in a cascade impactor operated at different humidity levels revealed how delivery and deposition performance of aerosols can be affec...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

...completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-contr...ange of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinan...

Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

...on of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, Mi...

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

...eloped for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficac...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

...eloped for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficac...

New Proton Therapy Equipment Enables More Tumors to be Treated

...e past four years by IBA in collaboration with Massachusetts General Hospital and the UF Proton Therapy Institute. IBA is the leading manufacturer of particle therapy equipment, with international headquarters in Belgium and a United States proton therapy headquarters in Jacksonville. "The immediate adv...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

...f the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, ...ange of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, recombina...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

...croparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ti...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additio...

Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additio...

NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional...

NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional ...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

... results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer ...antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was ...

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional...

Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional...

Particle Sciences Expands Its Combination Product Capabilities

... BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- particle Sciences Inc. has expanded its Combination Product...drug loaded polymeric devices. This addition gives particle Sciences the ability to go from bench scale to clinical trial material production. particle Sciences has recently completed Phase I of the dev...

Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's

...on, half of the radioactivity is lost every 20 minutes. This means that it must be manufactured onsite, a process that requires a cyclotron (a type of particle accelerator), which is rarely found in community hospitals. This limitation has prompted a search for longer-lived tracers, such as 18F-labeled agents...

Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds

...s advantages over other procedures for lipoprotein particle analysis because it both measures particle size accurately on the basis of physical principle...he particles present at each size independently of particle composition. We believe this approach provides the...

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

...eclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology. "Until now, it has been difficult to produce VLP vaccin...ange of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant...

Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent recombinant vaccines utilizing a new, efficient manufacturing solution. Additional info...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

...EL, Wheeler C, Ferris DG, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 ... et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from r...

FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.

...e ETDRS chart at 12 months. In contrast to previous forms of radiation therapy for wet AMD, NeoVista's therapy delivers a one-time peak dose of beta particle energy (24 Gy) directly to the lesion, and the normal retinal vasculature receives minimal exposure. Utilizing strontium 90, the focused energy is del...

Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate

...l stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution. Forwar...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

...euticals' proprietary Tempo inhaler. MAP0005 uses the Company's proprietary particle technology to combine the corticosteroid and beta-agonist components into a single drug particle in a fixed, pre-specified ratio. MAP Pharmaceuticals believes this combinat...

Novavax Reports Fourth Quarter and 2007 Year-End Financial Results

...y creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the Company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral d...

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial

... to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies." Known as TIGER-...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

...et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from ...thKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16...

Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program

...y creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral d...

Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program

...clinical studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of tw...than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines...

GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution

...hcare's bioprocess solutions and design expertise and Novavax's virus- like particle (VLP) and manufacturing platform. Health planners around the world are lo...than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines...

Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

...nd development costs related to advancing the Company's two lead virus-like particle ("VLP")-based vaccine candidates against pandemic and seasonal influenza. ...than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines...

Novavax CEO to Present at ACUMENBioFin's 9th Annual Healthcare Conference

...y creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral d...

Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission

... scale, The Eclipse family of PET cyclotrons is Siemens solution for radioisotope production. The Eclipse cyclotron is an 11 MeV, negative ion, single particle accelerator designed for clinical and commercial production and distribution of 18-fluoride-based radiotracers, as well as production N- 13, 0-15 and ...

Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference

... results of pre-clinical immunological studies of improved HIV-1 virus-like particle (VLP) vaccines being developed by scientists at Novavax and leading vaccine...han current preventives options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines...

Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol

.... 5 in the journal Nature Structural & Molecular Biology in a paper entitled "The Refined Structure of Nascent HDL Reveals a Key Functional Domain for particle Maturation and Dysfunction." It builds upon the researchers' previous work which determined that not all HDL helps protect arteries from becoming clog...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

... in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed to induce a potent Th1 type immune response in order to...
Other Tags
(Date:7/23/2014)... Protection Agency (EPA) today announced that environmental health ... Amherst School of Public Health and Health Sciences ... Achieve Results (STAR) grant to measure indoor air ... in subarctic North America to determine possible health ... culturally-relevant recommendations for mitigation. , Peltier, who will ...
(Date:7/23/2014)... about the crow and the pitcher, a thirsty bird happens ... drink from it, he finds the water level out of ... the bird drops pebbles into it one at a ... to drink his fill. , Highlighting the value of ingenuity, ... effective than brute force. It also characterizes crows as pretty ...
(Date:7/23/2014)... U.S. Department of Defense recently awarded the STEMPREP ... grant to support its goal of increasing the ... bright, science-minded minority middle school students for the ... provides high school students with summer opportunities at ... Annette Caldwell Simmons School of Education and Human ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... powerful drug combo may not be as effective against ... human cells suggests that one of the medications might ... study,s findings aren,t definitive, and there,s still hope for ... lumacaftor, according to the study,s senior author. "The ...
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... 23, 2014 The next episode of ... Milwaukee, Wis. who was physically fit through childhood and ... ultimately made the heart-wrenching decision to give her son ... the past 18 years, and she punished herself by ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Celebrating a ... New Jersey today announced the awarding of $1,070,000 in ... special award in recognition of the Foundation’s 1,000th grant. ... to continue our tradition of supporting community-based organizations that ... quality of life in the Garden State,” said Robert ...
Breaking Medicine News(10 mins):Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5
Other Contents